manilatimes4 天
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung ...
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...
来自MSN6 天
Future Perspectives and Challenges in Recombinant Antibody Development
Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...